top of page
WIN-B
CLINICAL STUDY TO EVALUATE DEBIO0123 + SACITUZUMAB GOVITECAN COMBINATION IN TNBC OR HR+/HER2- ADVANCED BREAST CANCER (WIN-B)
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE IS TO EVALUATE DEBIO 0123'S RP2D WHEN ADMINISTERED IN COMBINATION WITH SACITUZUMAB GOVITECAN, SAFETY AND EFFICACY OF THIS COMBINATION THERAPY IN ADVANCED/METASTATIC BREAST CANCER PATIENTS. PATIENTS AGED ≥ 18 YEARS WITH TNBC OR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER RELAPSING AFTER ONE OR TWO LINES OF TREATMENT ARE ELIGIBLE TO PARTICIPATE IN THE STUDY.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Breast cancer
8
76 (Ib: 8, II: 25)
Ib/II
Spain, UK, US
Recruitment
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
-----
TRIAL SITES
Hospital Arnau de Vilanova de Valencia (Spain)
Hospital Beata María Ana (Spain)
Hospital Universitario Virgen de la Victoria (Spain)
Beatson West of Scotland Cancer Centre (UK)
Hospital Universitari Dexeus (Spain)
Hospital Universitario Clínico San Cecilio de Granada (Spain)
Velindre University NHS Trust (UK)
Hospital Universitario San Juan Alicante (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page